Once again, biotech investors are reminded that a slow day on the markets doesn't guarantee we'll be drama free in the health-care sector. We had several big moves and a few notable headlines grabbing investor attention. Let's dive into two of those stories and highlight key investor takeaways.
This morning, shares traded for under cash on hand, although for an unprofitable biotech, cash is certainly a moving target. Before investors jump in with real money, though, remember that just because Targacept has institutional support, that doesn't mean its drug will be successful; Alzheimer's is a particularly tough disease to crack. Just ask Elan
For an in-depth look at the hottest stock in biotech, try The Motley Fool's new premium report on Arena Pharmaceuticals. This report outlines key opportunities and risks facing the company plus the must-watch areas for investors. Click here to receive your copy now!
David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is Eli Lilly and Company a Buy in 2018?
The outlook is complicated for this big pharma stock.
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
A robust clinical-stage pipeline helped investors forget about Arena's ill-fated weight-loss drug.